Unaudited Financial Results (Standalone & Consolidated) for the third quarter and Nine Months Ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.1 pts more than Nifty Microcap 250 and 8.3 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Titan Biotech reported a strong Q3 FY26 with standalone revenue from operations of Rs. 5,650.57 lakhs, up roughly 47.6% year-on-year versus Rs. 3,827.58 lakhs in Q3 FY25. For nine months FY26, standalone revenue grew about 29.7% YoY to Rs. 15,735.68 lakhs. Standalone profit after tax jumped nearly 107% YoY in Q3 to Rs. 786.82 lakhs, and rose about 44% YoY to Rs. 2,089.15 lakhs for the nine-month period. Basic EPS for Q3 stood at Rs. 9.52 versus Rs. 4.60 a year ago, while nine-month EPS reached Rs. 25.28. On a consolidated basis, including share of profits from associates Peptech Biosciences and Titan Media, nine-month PAT was Rs. 2,315.61 lakhs (up ~32% YoY) with consolidated EPS of Rs. 28.02. The statutory auditor issued an unmodified limited review report with no qualifications, and there were no exceptional items during the period.
Broadly positive for shareholders — strong double-digit revenue and profit growth on both standalone and consolidated basis, no exceptional items, clean auditor review, and the consolidated earnings also benefit from associate contribution. Likely to be viewed favorably by the market.